Welcome to NeurologyLive® Brain Games! This weekly quiz series, which goes live every Sunday morning, will feature questions ...
PROPEL will test imeroprubart, an investigational FcRn blocker, against placebo in adults with mild to severe generalized ...
New data from a Cure SMA survey showed that children treated with disease-modifying therapy soon after birth walk more often and have fewer comorbidities than those treated later. An updated ...
Treatment initiation before 90 days correlated with markedly higher independent walking (73.2% vs 36.7%) and fewer ...
Cluster headache care remains hindered by migraine overlap, contributing to diagnostic delay and prolonged unmet need for ...
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Dravet syndrome treatment ...
The professor of neurology at the University of Lyon and 2026 Rachel Horne Prize Winner discussed pregnancy counseling, ...
The investigators set out to indirectly compare nipocalimab's safety, specifically any adverse event (AE) and any serious ...
Congressional passage would extend ACT for ALS programs and associated research grants through FY2031, sustaining federal ...
Tasimelteon advanced sleep onset by 42.5 minutes versus 5.4 minutes with placebo in DSWPD, meeting the primary endpoint with ...
The FDA has approved tavapadon (AbbVie), a once-daily oral selective dopamine D1/D5 receptor partial agonist, for adults with ...
A prospective, multicenter real-world study, dubbed ADHERE REAL (NCT07264426), will evaluate the effectiveness of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results